platelets from SLE patients. MS analysis revealed 32 proteins with ≥ 1.5 -fold difference and a p-value of less than 0.05 (Abundance Ratio Adjusted). STAT1, ISG15, NMI and TRIM25 were among 19 proteins expressed at higher levels in small platelets and unbiased enrichments analyses showed a significant overrepresentation of proteins related to type I interferon signaling.

Conclusions The increased mitochondrial depolarization in platelets from SLE patients is an indication but not conclusive evidence of increased platelet apoptosis. Interestingly, decreased sized platelets from SLE patients showed an up regulation of type I interferon related proteins, suggesting direct or indirect influence of IFN. This is a novel finding that may suggest that platelet size is related to IFN signaling. Further studies will be conducted to investigate the mechanistic and potential clinical role of this finding.

P29 CLINICAL RELEVANCE OF DFS70 ANTIBODIES AT A COMMUNITY HOSPITAL

¹Ana Rita Maia, ²Ana Sofia Pinto, ^{2,3}Joana Ferreira, ^{2,3}Cláudia Vaz. ¹ULS Guarda, Guarda; ²Dept. Rheumatology, ULS Guarda, Guarda; ³Faculty of Health Sciences, University of Beira Interior, Covilhã, Portugal

10.1136/lupus-2020-eurolupus.77

Background/Purpose Antinuclear antibodies (ANA) are a serological hallmark of systemic autoimmune rheumatic diseases (SARD), such as systemic lupus erythematosus (LES), Sjögren's syndrome, systemic sclerosis and mixed connective tissue disease. Indirect immunofluorescence using human epithelial cells (HEp-2) is the gold standard for ANA screening. The nuclear pattern dense fine speckled (DFS) is one of the most common found when ANA levels are increased. DFS70 antibodies have been detected in inflammatory and neoplastic diseases; in contrast they are rare in SARD. These findings lead to research about their clinical implications. The aims of this study are: understand the meaning of anti-DFS70 antibodies; recognize the relevance of these antibodies in the diagnosis of patients with increased ANA titers in the context of SARD and non-rheumatic pathology (NRP).

Methods A retrospective observational study of consecutive patients observed during 2018 in a community hospital with anti-DFS70 antibodies positivity were performed. Sex, age, clinical and autoantibodies associations were recorded. Ethical approval was obtained and it was executed in compliance with the Helsinki Declaration.

Results Of forty-seven patients 38 (80.9%) were females; mean of age was 51,57 years; 10 (21.3%) were diagnosed with SARD (among which 4 were LES, 5 rheumatoid arthritis and 1 had autoimmune thyroiditis); 10 (21.3%) NRP (2 with asthma, 1 allergic rhinitis, 1 sinusitis, 1 urticaria, 1 vitiligo, 2 neoplasia and 2 Gilbert's syndrome) and 27 (57.4%) had no pathology associated - 4 patients of them presented positive antibodies without SARD.

Conclusions Although DFS70 antibodies are not specific for a particular condition, our study shows that they are a useful biomarker for differentiating between SARD and NRP when others antibodies are presented and it should be considered as a negative predictor for SARD if no other antibody is present. Whereby, DFS70 should be integrated into ANAs initial interpretation algorithm to avoid further studies.

P30 A CUSTOM-MADE MICROARRAY FOR DETECTION OF AUTOANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS

¹Linda Mathsson-Alm, ¹Kerstin Anger, ¹Jorge Dias, ²Henny Otten, ³Tammo Brunekreef, ⁴Sascha Swiniarski, ¹Maryam Poorafshar. ¹Thermo Fisher Scientific, Uppsala, Sweden; ²Center of Translational Immunology, UMC Utrecht, Utrecht, The Netherlands; ³Dept. of Rheumatology and Clinical Immunology, UMC Utrecht, Utrecht, The Netherlands; ⁴Thermo Fisher Scientific, Freiburg, Germany

10.1136/lupus-2020-eurolupus.78

Background Systemic Lupus Erythematosus (SLE) is a heterogeneous autoimmune disease associated with chronic inflammation with progressive organ degeneration. Early diagnosis intervention is crucial to improve overall disease course. Anti-dsDNA antibodies are the most sensitive serological biomarkers for SLE. The available diagnostic methods, however, identify different antibody subpopulations against dsDNA leading to varying performance. Thus, a serological biomarker profile specific to aid timely diagnosis and sensitive for disease activity of SLE remains an important clinical unmet need.

In this study a microarray was developed that enabled a simple and rapid characterization of the serological profile of SLE patients. In this microarray it was possible to analyze up to 90 autoantibodies in $<10 \mu\text{l}$ serum, making it a useful tool for characterization of SLE patient cohorts.

Methods A microarray was developed by spotting autoantigens in an arrayed fashion onto the surface of maxisorp plastic slides. Binding of each antigen was optimized regarding concentration and spotting buffer. The assay was performed by incubating diluted serum on the array followed by incubation with a fluorescent-labeled anti-human IgG antibody. Fluorescence intensities were measured with a laser scanner and the resulting images analyzed with an image analysis software. The microarray performance was compared to single analytes on EliA™ (Phadia AB, Uppsala, Sweden). For technical evaluation serum from 160 SLE patients and 313 healthy blood donors were measured.

Results Overall, there was strong correlations between microarray and EliA results for relevant biomarkers. The mean CV% between productions, lots and assays were 11, 8 and 7%, respectively.

Conclusions The developed microarray showed good technical performance and is a promising tool for the characterization of the serological profile of SLE patients. Furthermore, it has been applied in a clinical study as a discovery tool for new autoantibodies and patterns of autoantibodies with promising results.

P31 ANTI-DOMAIN I POSITIVITY IN SLE AT DIAGNOSIS IS PREDICTIVE OF ATHEROSCLEROTIC PLAQUE DEVELOPMENT

¹Thomas McDonnell, ¹Filipa Farinha, ²Charis Pericleous, ³Maura Griffin, ³Andrew Nicholaides, ¹Sara Croca, ¹Ian Giles, ¹Anisur Rahman. ¹Rheumatology, Division of Medicine, University College London, London; ²Vascular Dept., Imperial College London, London; ³Vascular Non-invasive Diagnostic Centre, London, UK

10.1136/lupus-2020-eurolupus.79

Background Cardiovascular disease is a significant burden on SLE patients and no satisfactory markers exist to predict atherosclerotic development in patients. This study utilised an orthogonal approach to develop a marker of cardiovascular progression with predictive value in SLE patients.

Methods The earliest available sample from a cohort of 92 SLE patients was tested for anti-Domain I (aDI), anti Beta-2-Glycoprotein-I, and anti-Cardiolipin antibodies. Persistent positivity was not assessed. These patients then had vascular ultrasound scans (carotid and femoral arteries) (mean 10 years later) to assess subclinical atherosclerotic plaque. A range of demographic, clinical and serological markers were recorded at the time of the scan. Predictors of plaque presence were investigated using binary logistic regression.

Results A total of 34 patients from the cohort of 92 had atherosclerotic plaque (37%). A total of 32 patients had aDI positivity, of which 20 (62.5%) also had Plaque, this is reflected by the significantly higher levels of aDI antibodies seen in Plaque patients ($p < 0.01$, figure 1). Anti-DI positivity was predictive of the development of plaque in the future (Odds Ratio (OR) 5.476, $p < 0.001$). No association was seen for any other antibody tested. Multiple binary logistic regression showed aDI positivity had as much predictive value as triglyceride levels on the day of the scan (OR 3.5 vs 3.9, table 1) for predicting plaque in patients. Age at scan was a third independent variable associated with atherogenic plaque.

Abstract P31 Figure 1 A significantly higher level of aDI antibody was seen in plaque patients in comparison to non-plaque patients.

Abstract P31 Table 1 Binary logistic regression showing the odds ratios associated with aDI positivity, age at scan and triglyceride levels

	OR	95% C.I.		p
		Lower	Upper	
AntiD1 positive	3.512	1.137	10.849	.029
Age at Scan >50	10.517	3.479	31.794	.000
Triglyceride Level	3.869	1.155	12.957	.028

Conclusions Early aDI positivity may be a good marker of atherogenesis in SLE patients in the long term.

P32

ASSESSMENT OF LEFT VENTRICULAR USING SPECKLE TRACKING ECHOCARDIOGRAPHY AND ITS RELATIONSHIP WITH INSULIN RESISTANCE IN NON-DIABETIC PATIENTS WITH SLE

¹Claudia Mendoza-Pinto, ¹Pamela Munguía-Realpozo, ²Liliana Aquino, ¹Adalberto Ramírez-Hernández, ²Roberto Berra-Romani, ¹Aurelio López-Colombo, ¹Mario García-Carrasco. ¹High-Specialty Medical Unit-CIBIOR, Mexican Social Security Institute, Puebla; ²Medicine School, Meritorious Autonomous University of Puebla, Mexico

10.1136/lupus-2020-eurolupus.80

Background/Purpose Insulin resistance (IR), which adversely impacts left ventricular (LV) remodeling and function in middle-aged patients.¹ Although IR may not play as marked a role in determining LV dysfunction as hypertension, the impact of IR on ventricular dysfunction is unknown in SLE patients.² The aims of this study were: 1) to determine the role of speckle tracking echocardiography in the early detection of LV dysfunction in SLE and 2) to examine the influence of IR measured by the Quantose score on subclinical LV dysfunction using speckle tracking echocardiography in normotensive SLE patients.

Methods This cross-sectional study included SLE adult women without diabetes mellitus (DM), hypertension or obesity. All participants underwent detailed two-dimensional Doppler and two-dimensional speckle tracking echocardiography. Global longitudinal strain (GLS%) and global circumferential strain (GCS%) were determined. LV diastolic dysfunction (LVDD) was verified according to current guidelines. Blood samples were drawn to estimate the Quantose score for IR, (derived from insulin, α -hydroxybutyrate, linoleoyl-glycerophosphocholine, and oleate).

Results Sixty-nine patients were included (mean age: 38.9 ± 9.9 years, mean disease duration 10.8 ± 4.7 years). Despite a normal ejection fraction in all participants, ten (14.5%) patients had abnormal LV systolic GLS. The frequency of IR was high (65%). The GLS% and GCS% did not differ in patients with and without IR (-20.8 ± 3.1 vs. -20.5 ± 2.1 ; $p = 0.61$ and -25.9 ± 8.4 vs. -24.4 ± 9.3 ; $p = 0.47$, respectively). The prevalence of LVDD was 38.1% in patients with IR vs. 25.0% in patients without IR ($p = 0.30$). E/e' and E/A ratios did not differ significantly between groups (5.8 ± 1.6 vs. 5.7 ± 1.9 ; $p = 0.86$ and 1.3 ± 0.3 vs. 1.3 ± 0.3 ; $p = 0.27$).

Conclusions Although IR was high in our patients with SLE, IR was not associated with either LV systolic dysfunction or LVDD in SLE patients without DM or hypertension.

REFERENCES

- Demmer R.T., Allison M.A., Cai J., et al. Association of Impaired Glucose Regulation and Insulin Resistance With Cardiac Structure and Function: Results From ECHO-SOL (Echocardiographic Study of Latinos). *Circ Cardiovasc Imaging* 2016;**9**; e005032.
- Tso T.K., Huang W.N. Elevation of fasting insulin and its association with cardiovascular disease risk in women with systemic lupus erythematosus. *Rheumatol Int* 2009;**29**:735–74.